Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
McKinsey
McKesson
Colorcon
Boehringer Ingelheim

Last Updated: September 30, 2022

Details for Patent: 7,105,530


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,105,530 protect, and when does it expire?

Patent 7,105,530 protects VOTRIENT and is included in one NDA.

This patent has forty patent family members in twenty-five countries.

Summary for Patent: 7,105,530
Title:Pyrimidineamines as angiogenesis modulators
Abstract:Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also Includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
Inventor(s): Boloor; Amogh (Lubbock, TX), Cheung; Mui (Durham, NC), Davis; Ronda (Durham, NC), Harris; Philip Anthony (Durham, NC), Hinkle; Kevin (Durham, NC), Mook, Jr.; Robert Anthony (Durham, NC), Stafford; Jeffery Alan (San Diego, CA), Veal; James Marvin (Durham, NC)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:10/451,305
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,105,530

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,105,530

PCT Information
PCT FiledDecember 19, 2001PCT Application Number:PCT/US01/49367
PCT Publication Date:August 01, 2002PCT Publication Number: WO02/059110

International Family Members for US Patent 7,105,530

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 430742 See Plans and Pricing
Australia 2002246723 See Plans and Pricing
Brazil 0116452 See Plans and Pricing
Canada 2432000 See Plans and Pricing
China 1307173 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
McKinsey
Boehringer Ingelheim
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.